CureVac Recognized as a Global Innovator by LexisNexis

CureVac N.V., a biopharmaceutical company specializing in mRNA technology, has been named a Top 100 Global Innovator by LexisNexis for the third year in a row. This accolade recognizes companies with cutting-edge patent portfolios that advance innovation across industries. CureVac's consistent recognition underscores its leading role in mRNA science, boasting one of the most extensive intellectual property portfolios in this field.

The company's pioneering work over the last 25 years has significantly contributed to the development of mRNA-based solutions, including COVID-19 vaccines. Its 1,000 issued patents cover a broad range of innovations in mRNA technology, delivery, and manufacturing.

The LexisNexis Innovation Momentum 2025 report evaluates the impact and potential of patent portfolios, rewarding companies like CureVac that maintain high-quality, influential patent holdings. CureVac's innovations continue to play a crucial role in global health advancements and the future of medicine.